Clinical Trial: NCT04696731
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Allogene Therapeutics |
| Information Provided By: | Allogene Therapeutics |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
Official Title
Conditions
Intervention / Treatment
- Genetic: ALLO-316
- Biological: ALLO-647
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- ALLO-316-101
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Allogene Therapeutics |
| Information Provided By: | Allogene Therapeutics |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
Official Title
Conditions
Intervention / Treatment
- Genetic: ALLO-316
- Biological: ALLO-647
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- ALLO-316-101